What Cmbio does

Cmbio is a Copenhagen-headquartered microbiome and multi-omics research services company formed through the fusion of four specialized firms — Clinical Microbiomics, CosmosID, DNASense, and MS-Omics. It serves academic researchers, pharmaceutical and biotech companies, healthcare and clinical organizations, food safety producers, and environmental/agricultural research groups, delivering end-to-end laboratory analysis and data interpretation for human, animal, and environmental health applications. The company employs a team of over 100 experts spanning microbiology, bioinformatics, metabolomics, molecular biology, and data science, operating laboratories in Denmark and the United States with commercial reach across US, EU, and APAC regions.

Technically, Cmbio's offering is organized into three pillars: (1) Omics sequencing services including shotgun and long-read metagenomics, 16S rRNA/marker gene analysis, microbiome profiling, absolute abundance, metabolomics, transcriptomics/metatranscriptomics, proteomics, and metaproteomics; (2) Bioinformatics services including biostatistics, integrative systems biology/multi-omics integration, strain tracking and engraftment, and machine learning/AI analysis; and (3) the Cosmos-HUB (CosmosID-HUB) cloud-based bioinformatics platform for scalable data analysis and visualization. Differentiated technical components include proprietary Clonal-Level Microbiomics for strain-level resolution, GxP-compliant laboratory processes for regulatory-ready clinical and pharmaceutical work, and eDNA metabarcoding for environmental species identification.

Commercially, Cmbio operates as a B2B research-services business with a consultative, direct field-sales motion in which specialized scientists collaborate with clients on study design, method selection, and data interpretation. Revenue is generated primarily through project-based professional services (contract sequencing and bioinformatics), sampling kits and project handling, and access to the Cosmos-HUB software platform. Pricing is quote-based and not publicly disclosed, varying by sample type, sample count, sequencing depth, analysis requirements, and project complexity, with inbound demand captured via "Request a meeting" forms and direct contact; the company is GDPR-compliant and operates under Danish jurisdiction.

Name

Cmbio

Legal name

Cmbio

Website

https://cmbio.io

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Cmbio provides laboratory sequencing, bioinformatics, and cloud-based data analysis services for microbiome and multi-omics research, serving academic, pharmaceutical, clinical, food safety, and environmental clients across human, animal, and environmental health applications from labs in Denmark and the US.

Ownership category

akta.pro rank

Product category

Microbiome Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiome & Metagenomics Services (HLAGANAH)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Microbiome sequencing services
• Multi-omics analysis
• Bioinformatics data analysis
• Metagenomics research
• Strain-level identification

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Microbiome Research Services: End-to-end microbiome research services including sequencing (metagenomics, metabolomics, transcriptomics, proteomics), bioinformatics analysis, and project handling. Services are provided on a contract basis with specialized scientists collaborating directly with clients on analytical techniques, method selection, and data interpretation.
2. Bioinformatics and Data Analysis: Advanced bioinformatics services including biostatistics, integrative systems biology, multi-omics integration, strain tracking, and machine learning/AI-powered analysis. Provided as standalone services or integrated with sequencing services.
3. Sampling Kits and Project Handling: Custom kits for efficient microbiome sample collection, preservation, and transport tailored to study needs and logistics. Includes kitting services for research projects.
4. Software Platform (Cosmos-HUB): Cloud-based software platform for microbiome data analysis available to researchers and companies for their own analysis needs

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Cmbio provides end-to-end microbiome and multi-omics laboratory services, including shotgun metagenomics, long-read metagenomics, marker gene analysis, metabolomics, transcriptomics, proteomics, and metaproteomics sequencing, complemented by advanced bioinformatics analysis and the Cosmos-HUB cloud platform for scalable data interpretation. The company serves researchers and organizations across human health, animal health, and environmental applications through a consultative sales model with specialized scientists.

Product overview

Cmbio is a unified multi-omics services platform formed by the fusion of Clinical Microbiomics, CosmosID, DNASense, and MS-Omics. The company provides end-to-end microbiome research services organized into three main pillars: (1) Omics Services including shotgun metagenomics, long-read metagenomics, marker gene analysis, microbiome profiling, metabolomics, transcriptomics, proteomics, and metaproteomics; (2) Bioinformatics Services including integrative systems biology, biostatistics, strain tracking, and machine learning/AI services; and (3) Software Platform through Cosmos-HUB for cloud-based data analysis. Services span human health, animal health, and environmental applications including gut microbiome research, eDNA metabarcoding, food safety, and agriculture. The architecture combines laboratory sequencing services with advanced bioinformatics and AI-powered analytics delivered through a cloud-based platform.

Differentiator

Problem solved

Functional benefit

Brands

• Cosmos-HUB: Cloud-based bioinformatics platform for microbiome data analysis
• CosmosID
• Clonal-Level Microbiomics

Products and services

• Cosmos-HUB

Quantifiable outcome

• eDNA sampling identifies more species than traditional methods (42 fish species vs 33 via trawl nets)
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

One partnership is on record.

• CosmosIDcoreOthersCosmosID is one of the founding companies that merged to form Cmbio. CosmosID's technology and capabilities in microbial sequencing and bioinformatics are integrated into Cmbio's service offerings, including the CosmosID-HUB platform for microbiome analysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• QIAGEN Digital Insights: Provides CLC bio, microbial genomics, and clinical bioinformatics software plus companion services — comparable through its bioinformatics platform and growing microbiome/wet-lab offerings, anchored by a much larger installed base.
• Novogene: Large genomics CRO offering microbial whole-genome sequencing, metagenomics, and bioinformatics with global lab capacity — directly competes in multi-omics project services, often at lower price points.
• Eurofins Genomics (CoreBiome): Eurofins acquired CoreBiome to offer end-to-end microbial genomics services alongside a global lab network; comparable as a full-service microbiome sequencing and bioinformatics provider, but embedded in a much broader testing portfolio.
• Illumina (sequencing and BaseSpace): Dominant sequencing platform vendor whose instruments and BaseSpace/cloud ecosystem shape the competitive set Cmbio operates in — vertical integration threats make it a relevant adjacent incumbent despite its different primary business.

Direct peers

• LC Sciences: Multi-omics services company providing sequencing, metabolomics, and bioinformatics across microbiome, transcriptomics, and epigenetics — overlaps substantially with Cmbio's omics and bioinformatics service lines.
• Diversigen: Microbiome sequencing and analysis services company focused on DNA/RNA extraction, library prep, sequencing, and custom bioinformatics — directly comparable services and customer profile to Cmbio, now within OraSure.
• Zymo Research: Provides microbiome collection devices, DNA extraction kits, and shotgun metagenomic sequencing services — directly comparable to Cmbio's sampling-kit-plus-sequencing services for academic and clinical microbiome customers.
• CD Genomics: Offers shotgun metagenomics, 16S amplicon sequencing, metatranscriptomics, metabolomics, and bioinformatics services to researchers and pharma — a near-direct multi-omics services competitor with similar project-based, quote-driven GTM.
• MRDNA (Molecular Research): Specializes in microbial identification and microbiome sequencing services using 16S and shotgun approaches, with bioinformatics reporting — comparable mid-sized microbiome CRO serving academic and industrial researchers.

Emerging players

• CosmosID (legacy brand inside Cmbio): The CosmosID brand that merged into Cmbio and contributed the Cosmos-HUB platform; included for context as the same technology stack now marketed under Cmbio, with overlap on microbial identification databases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cmbio
• Xx.com/ClinMicrobiom

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cmbio